223 related articles for article (PubMed ID: 29726292)
1. Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?
Liao BC; Lin CC; Yang JC
Expert Opin Pharmacother; 2018 Jun; 19(8):851-864. PubMed ID: 29726292
[TBL] [Abstract][Full Text] [Related]
2. Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.
Wrona A; Dziadziuszko R; Jassem J
Cancer Treat Rev; 2018 Dec; 71():59-67. PubMed ID: 30366200
[TBL] [Abstract][Full Text] [Related]
3. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.
Metro G; Chiari R; Ricciuti B; Rebonato A; Lupattelli M; Gori S; Bennati C; Castrioto C; Floridi P; Minotti V; Chiarini P; Crinò L
Expert Opin Pharmacother; 2015; 16(17):2601-13. PubMed ID: 26439599
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
[TBL] [Abstract][Full Text] [Related]
6. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Toyokawa G; Seto T; Takenoyama M; Ichinose Y
Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
[TBL] [Abstract][Full Text] [Related]
7. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Kashima J; Okuma Y; Miwa M; Hosomi Y
Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
[TBL] [Abstract][Full Text] [Related]
9. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
[TBL] [Abstract][Full Text] [Related]
10. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
Chen YM
J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
[TBL] [Abstract][Full Text] [Related]
11. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
[TBL] [Abstract][Full Text] [Related]
12. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
Jiang T; Su C; Li X; Zhao C; Zhou F; Ren S; Zhou C; Zhang J
J Thorac Oncol; 2016 Oct; 11(10):1718-28. PubMed ID: 27237825
[TBL] [Abstract][Full Text] [Related]
13. Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastases.
Thomas CM; Lee CS
J Oncol Pharm Pract; 2019 Apr; 25(3):623-637. PubMed ID: 30176786
[TBL] [Abstract][Full Text] [Related]
14. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
15. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L
J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436
[TBL] [Abstract][Full Text] [Related]
16. EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
Bartolotti M; Franceschi E; Brandes AA
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1429-35. PubMed ID: 23249107
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.
Iwama E; Nakanishi Y; Okamoto I
Expert Rev Anticancer Ther; 2018 Mar; 18(3):267-276. PubMed ID: 29363369
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy of Treatments for Brain Metastases from Non-Small Cell Lung Cancer without an EGFR-Mutation/ALK-Rearrangement: A Systematic Review and Network Meta-Analysis.
Brar K; Taslimi S; Ellenbogen Y; Deng J; Hou W; Moraes FY; Glantz M; Zacharia BE; Tan A; Ahluwalia MS; Khasraw M; Zadeh G; Mansouri A
World Neurosurg; 2022 Feb; 158():e87-e102. PubMed ID: 34688937
[TBL] [Abstract][Full Text] [Related]
20. [Timing of Whole Brain Radiotherapy on Survival of Patients with EGFR-mutated
Non-small Cell Lung Cancer and Brain Metastases].
Liu G; Zhang X; Tian C; Xia G; Liu P; Zhang Q; Li X; Zhang H; Qin N; Wang J; Zhang S
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):501-7. PubMed ID: 27561798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]